Silicon Valley Answered Falling Births With Embryo Scores

The country keeps having fewer babies, and the Valley keeps shipping a dashboard. Provisional CDC data for 2025 put the U.S. general fertility rate at 53.1 births per 1,000 women ages 15 to 44, another record low, with roughly 3.6 million births. The rate has fallen about 23 percent since 2007. That is the factual floor under the panic. What Silicon Valley does with the panic is the story.

Pronatalism is the movement that treats low birth rates as civilizational emergency. Elon Musk, father of at least fourteen children by public count, calls population collapse one of the biggest risks to civilization. Sam Altman talks about a big family and has put money into experimental fertility tech. Coinbase's Brian Armstrong and Peter Thiel have backed the polygenic embryo screening stack. The talking points sound like natal policy. The invoices look like biotech.

5 min read

Orchid Health and Nucleus Genomics sell genetic information about IVF embryos so parents can choose which one to implant. Traditional clinic screening looks for chromosomal catastrophes and single-gene diseases. These startups push further into polygenic risk scores for complex traits: diabetes, heart disease, and, in Nucleus's marketing orbit, appearance and IQ. Orchid has charged upward of $2,500 per embryo for polygenic disease screens. Nucleus has floated embryo ranking products in the several-thousand-dollar range, on top of IVF cycles that often clear $20,000 before the genetics bill.

The American Society for Reproductive Medicine has cautioned that polygenic testing should not be used for non-medical trait selection and that clinical utility remains unproven. Britain and other countries have largely blocked polygenic scores for embryo choice. In the United States the FDA has mostly stayed out of this direct-to-consumer lane. The product ships anyway. Venture capital does not wait for a Cochrane review.

Call the Valley's answer what it is. Quantity rhetoric plus quality tooling. Musk and the Natal Conference circuit want more births. The embryo companies want ranked births. Malcolm and Simone Collins, the movement's most visible couple, mix large-family advocacy with PGT-P selection and talk openly about differential fertility between high-productivity and low-productivity groups. That is where the soft language of civilization meets the hard language of stock.

Washington has noticed the birth chart. A $1,000 Trump account baby bonus for new U.S. citizen babies began rolling out in July 2026, a thin check against the cost of raising a child. Motherhood medals and larger cash bonuses were floated and mostly shelved. None of that rebuilds housing near jobs, paid leave, or childcare that does not eat a second income. Silicon Valley's preferred lever is upstream of all that: make the pregnancy optional until a report card arrives.

A falling fertility rate is a real policy problem. Aging societies strain pensions and hospitals. Treating it as a ranking problem is a category error with a pitch deck. Scores built from weak predictive models get sold as parental love, the way Orchid's Noor Siddiqui has compared embryo selection to planning a nursery. Love does not usually come with a discard pile. The Valley answered the birth drought by turning the next generation into inventory with probabilities attached. That may grow a market. It will not grow a country that people can afford to raise children in.